Dravet
56 programs · 54 companies
Programs
56
Companies
54
Trials
47
MOAs
41
CDK2iALKiMDM2iWRNiCD47iBCL-2iKRASG12CiIL-17iUSP1iSHP2i
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-3703 | Phase 1/2 | CDK2 | ||
| Miriosocimab | Phase 1 | PARP | ||
| Doxacapivasertib | Phase 3 | APOC3 | ||
| ABB-1817 | Phase 3 | SHP2 | ||
| AMG-7379 | Preclinical | DLL3 | ||
| Rimaosocimab | Preclinical | FXIa | ||
| ALN-6288 | Approved | LAG-3 | ||
| ARG-3458 | Preclinical | RET | ||
| Pexanaritide | Preclinical | SGLT2 | ||
| 369-4107 | Phase 2 | TNFα | ||
| Bemanaritide | Phase 2 | CD38 | ||
| DAW-8159 | Phase 2 | PSMA | ||
| RCK-5227 | Phase 1 | AuroraA | ||
| Tezesotorasib | Phase 2 | USP1 | ||
| GUS-IIT-540 | Phase 1/2 | TYK2 | ||
| SAM-IIT-954 | Phase 1/2 | EGFR | ||
| EOR-IIT-286 | Preclinical | CFTR | ||
| IMM-7074 | Phase 1/2 | WRN | ||
| CHI-3786 | Phase 2 | SOS1 | ||
| Pemizasiran | Phase 1/2 | MDM2 | ||
| Sovalucimab | NDA/BLA | TROP-2 | ||
| Adagracapivasertib | Approved | MALT1 | ||
| Motatenlimab | Preclinical | Tau | ||
| Terazasiran | Phase 2 | TROP-2 | ||
| Olpatinib | NDA/BLA | TNFα | ||
| Cevicilimab | Phase 3 | B7-H3 | ||
| CAL-4725 | Preclinical | WEE1 | ||
| Tiramavacamten | Phase 2/3 | CD47 | ||
| Suramavacamten | Phase 1 | TROP-2 | ||
| Bemasertib | Phase 1 | PLK4 | ||
| Suraosocimab | Phase 1/2 | FLT3 | ||
| MRN-8142 | Phase 2/3 | PI3Kα | ||
| Elrazasiran | NDA/BLA | EZH2 | ||
| ANT-256 | NDA/BLA | EZH2 | ||
| Polazumab | Phase 3 | KRASG12D | ||
| ORC-1969 | Phase 1 | Tau | ||
| 225-7610 | NDA/BLA | Tau | ||
| GLO-4270 | Phase 1 | CFTR | ||
| 109-1876 | Preclinical | WEE1 | ||
| ASK-5918 | Phase 2/3 | GLP-1R | ||
| Ivonaritide | Phase 2/3 | WRN | ||
| Daramavacamten | Preclinical | CFTR | ||
| Zanumavacamten | Phase 1/2 | DLL3 | ||
| TRI-2954 | Approved | FLT3 | ||
| Gozesertib | Phase 1/2 | CDK2 | ||
| MIR-1203 | Phase 1 | PD-1 | ||
| Surasertib | Phase 2 | PARP | ||
| Lisotuximab | Phase 1 | MET | ||
| ABD-3507 | Preclinical | VEGF | ||
| AMO-4131 | NDA/BLA | CD3 | ||
| AII-IIT-938 | Preclinical | WEE1 | ||
| Elrazanubrutinib | NDA/BLA | APOC3 | ||
| Tiratapinarof | Phase 3 | TYK2 | ||
| Tezevorutinib | Phase 1/2 | RET | ||
| 600-2840 | Phase 1 | JAK2 | ||
| SCI-2060 | Phase 2 | JAK1 |
Trials (47)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT08051536 | Miriosocimab | Phase 1 | Terminated |
| NCT05134858 | Miriosocimab | Phase 1 | Recruiting |
| NCT07715421 | Doxacapivasertib | Phase 3 | Completed |
| NCT03093432 | ABB-1817 | Phase 3 | Not yet recr... |
| NCT07937775 | AMG-7379 | Preclinical | Recruiting |
| NCT08855956 | Rimaosocimab | Preclinical | Not yet recr... |
| NCT07793748 | ALN-6288 | Approved | Terminated |
| NCT08826857 | Pexanaritide | Preclinical | Completed |
| NCT07261129 | Bemanaritide | Phase 2 | Terminated |
| NCT07767237 | DAW-8159 | Phase 2 | Active |
| NCT03267530 | DAW-8159 | Phase 2 | Not yet recr... |
| NCT07173503 | RCK-5227 | Phase 1 | Recruiting |
| NCT04181919 | Tezesotorasib | Phase 2 | Not yet recr... |
| NCT03446148 | Tezesotorasib | Phase 2 | Completed |
| NCT05143426 | GUS-IIT-540 | Phase 1/2 | Recruiting |
| NCT04426298 | SAM-IIT-954 | Phase 1/2 | Active |
| NCT06005558 | EOR-IIT-286 | Preclinical | Not yet recr... |
| NCT04759470 | IMM-7074 | Phase 1/2 | Terminated |
| NCT03368149 | Pemizasiran | Phase 1/2 | Active |
| NCT05931828 | Adagracapivasertib | Approved | Not yet recr... |